Novartis AG (NVS) Competitors & Peers
The 5 companies closest to Novartis AG on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,218.47 | P/E 39.6RSI 53Cap 1.05 T |
| JNJ | Peer | $261.81 | P/E 30.4RSI 58Cap 630.9 B |
| ABBV | Peer | $248.38 | P/E 69.7RSI 51Cap 439.7 B |
| MRK | Peer | $130.26 | P/E 102.6RSI 58Cap 321.4 B |
| AZN | Peer | $161.91 | P/E 24.2RSI 40Cap 251.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- REGNCompetitor
Novartis competes directly in the ophthalmology space (e.g., Lucentis and Beovu) against Eylea.
Model-inferred, unverified — treat as a lead, not evidence - ALNYPartner
Alnylam-Novartis Leqvio (inclisiran) for hypercholesterolemia.
Model-inferred, unverified — treat as a lead, not evidence - ERASPartner
Erasca co-develops combinations with Novartis MEK inhibitors.
Model-inferred, unverified — treat as a lead, not evidence - OCSPartner
Oculis in-licensed OCS-02 (licofelanem) TNF-alpha antibody droplet tech from Novartis.
Model-inferred, unverified — treat as a lead, not evidence - VERACompetitor
Vera's atacicept competes with Novartis's pipeline therapies for IgA nephropathy treatment.
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
Novartis uses Veeva Vault as a primary clinical/regulatory platform.
Model-inferred, unverified — treat as a lead, not evidence